U.S. License Holder:
Genzyme Corp.
Date of License:
August-06-2021
Last Update:
Sep-30-2024
FDA-Approved Indications
NEXVIAZYME (avalglucosidase alfa-ngpt) is a hydrolytic lysosomal glycogen-specific enzyme indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).